Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate
CONCLUSIONS: The plasma trough concentration of ABI is associated with the presence of AEs and treatment failure after AA administration. ABI concentration monitoring may be useful in patients with prostate cancer who received AA.PMID:36378297 | DOI:10.1007/s00228-022-03420-0 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - November 15, 2022 Category: Cancer & Oncology Authors: Yoshiko Takahashi Shintaro Narita Masaki Shiota Masatomo Miura Hideaki Kagaya Soki Kashima Ryohei Yamamoto Taketoshi Nara Mingguo Huang Kazuyuki Numakura Mitsuru Saito Masatoshi Eto Tomonori Habuchi Source Type: research
Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate
CONCLUSIONS: The plasma trough concentration of ABI is associated with the presence of AEs and treatment failure after AA administration. ABI concentration monitoring may be useful in patients with prostate cancer who received AA.PMID:36378297 | DOI:10.1007/s00228-022-03420-0 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - November 15, 2022 Category: Cancer & Oncology Authors: Yoshiko Takahashi Shintaro Narita Masaki Shiota Masatomo Miura Hideaki Kagaya Soki Kashima Ryohei Yamamoto Taketoshi Nara Mingguo Huang Kazuyuki Numakura Mitsuru Saito Masatoshi Eto Tomonori Habuchi Source Type: research
Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate
ConclusionsThe plasma trough concentration of ABI is associated with the presence of AEs and treatment failure after AA administration. ABI concentration monitoring may be useful in patients with prostate cancer who received AA. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - November 15, 2022 Category: Drugs & Pharmacology Source Type: research
Risk of cognitive impairment in men with advanced prostate cancer treated with novel hormonal agents: a systematic review and network meta-analysis
Clin Transl Sci. 2022 Nov 11. doi: 10.1111/cts.13451. Online ahead of print.ABSTRACTNovel hormonal agents (NHAs) have significantly improved outcomes in men with advanced prostate cancer. However, it remains unclear whether NHAs are associated with subsequent cognitive impairment. Thus, we sought to perform a network meta-analysis to compare the risk of cognitive impairment across NHA types. Databases (PubMed, Embase, Scopus, Web of Science), trial registries (Clinicaltrial.gov), EMA, and FDA drug safety reports were searched from inception through July 30, 2021. Eligible studies were clinical trials evaluating the risk of...
Source: Clinical Prostate Cancer - November 12, 2022 Category: Cancer & Oncology Authors: Shi-Wei Huang Li-Chin Chen Chi-Shin Tseng Chung-Hsin Chen Lun-Hsiang Yuan Wen-Yi Shau Yeong-Shiau Pu Source Type: research
Risk of cognitive impairment in men with advanced prostate cancer treated with novel hormonal agents: a systematic review and network meta-analysis
Clin Transl Sci. 2022 Nov 11. doi: 10.1111/cts.13451. Online ahead of print.ABSTRACTNovel hormonal agents (NHAs) have significantly improved outcomes in men with advanced prostate cancer. However, it remains unclear whether NHAs are associated with subsequent cognitive impairment. Thus, we sought to perform a network meta-analysis to compare the risk of cognitive impairment across NHA types. Databases (PubMed, Embase, Scopus, Web of Science), trial registries (Clinicaltrial.gov), EMA, and FDA drug safety reports were searched from inception through July 30, 2021. Eligible studies were clinical trials evaluating the risk of...
Source: Clinical Prostate Cancer - November 12, 2022 Category: Cancer & Oncology Authors: Shi-Wei Huang Li-Chin Chen Chi-Shin Tseng Chung-Hsin Chen Lun-Hsiang Yuan Wen-Yi Shau Yeong-Shiau Pu Source Type: research
Low TLR and PSMA-TV predict biochemical response to abiraterone acetate in metastatic prostate cancer patients developing castration resistance after chemohormonal therapy at hormone-sensitive stage
CONCLUSIONS: Low PSMA-TV, low TLR were vital independent predictors of biochemical response to AA treatment and were associated with preferable prognosis in mCRPC patients. Combining ADT duration, PSMA-TV and TLR performed well in distinguishing AA responders from non-responders in mCRPC patients.PMID:36333565 | DOI:10.1007/s00432-022-04438-8 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - November 5, 2022 Category: Cancer & Oncology Authors: Zhi-Bin Ke Jia-Yin Chen Qi You Jiang-Bo Sun Yu-Ting Xue Xiao-Jian Ye Shao-Hao Chen Xue-Yi Xue Xiong-Lin Sun Dong-Ning Chen Yong Wei Qing-Shui Zheng Shao-Ming Chen Ning Xu Source Type: research
Low TLR and PSMA-TV predict biochemical response to abiraterone acetate in metastatic prostate cancer patients developing castration resistance after chemohormonal therapy at hormone-sensitive stage
CONCLUSIONS: Low PSMA-TV, low TLR were vital independent predictors of biochemical response to AA treatment and were associated with preferable prognosis in mCRPC patients. Combining ADT duration, PSMA-TV and TLR performed well in distinguishing AA responders from non-responders in mCRPC patients.PMID:36333565 | DOI:10.1007/s00432-022-04438-8 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - November 5, 2022 Category: Cancer & Oncology Authors: Zhi-Bin Ke Jia-Yin Chen Qi You Jiang-Bo Sun Yu-Ting Xue Xiao-Jian Ye Shao-Hao Chen Xue-Yi Xue Xiong-Lin Sun Dong-Ning Chen Yong Wei Qing-Shui Zheng Shao-Ming Chen Ning Xu Source Type: research
Low TLR and PSMA-TV predict biochemical response to abiraterone acetate in metastatic prostate cancer patients developing castration resistance after chemohormonal therapy at hormone-sensitive stage
CONCLUSIONS: Low PSMA-TV, low TLR were vital independent predictors of biochemical response to AA treatment and were associated with preferable prognosis in mCRPC patients. Combining ADT duration, PSMA-TV and TLR performed well in distinguishing AA responders from non-responders in mCRPC patients.PMID:36333565 | DOI:10.1007/s00432-022-04438-8 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - November 5, 2022 Category: Cancer & Oncology Authors: Zhi-Bin Ke Jia-Yin Chen Qi You Jiang-Bo Sun Yu-Ting Xue Xiao-Jian Ye Shao-Hao Chen Xue-Yi Xue Xiong-Lin Sun Dong-Ning Chen Yong Wei Qing-Shui Zheng Shao-Ming Chen Ning Xu Source Type: research
Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients
ConclusionThe presence of Gleason pattern 5 at the primary lesion may be a predictor for high-risk mHSPC patients who could benefit from abiraterone acetate treatment. (Source: World Journal of Urology)
Source: World Journal of Urology - November 4, 2022 Category: Urology & Nephrology Source Type: research
Cancers, Vol. 14, Pages 5319: Range-Bounded Adaptive Therapy in Metastatic Prostate Cancer
ling
Adaptive therapy with abiraterone acetate (AA), whereby treatment is cycled on and off, has been presented as an alternative to continuous therapy for metastatic castration resistant prostate cancer (mCRPC). It is hypothesized that cycling through treatment allows sensitive cells to competitively suppress resistant cells, thereby increasing the amount of time that treatment is effective. It has been proposed that there exists a subset of patients for whom this competition can be enhanced through slight modifications. Here, we investigate how adaptive AA can be modified to extend time to progression using a simple ...
Source: Cancers - October 28, 2022 Category: Cancer & Oncology Authors: Brady-Nicholls Enderling Tags: Article Source Type: research
Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer
CONCLUSIONS This study demonstrated a trend toward a negative correlation between 3-month abiraterone trough levels and PSA levels, but the correlation was not statistically significant. A study with a larger prospective sample size is needed to validate these findings.PMID:36229939 | DOI:10.12659/MSM.938091 (Source: Medical Science Monitor)
Source: Medical Science Monitor - October 14, 2022 Category: Research Authors: Zin W Myint Jill M Kolesar Joseph Robert McCorkle Jianrong Wu Carleton S Ellis Danielle E Otto Peng Wang Source Type: research
Does Clinical Evidence of Heterogeneity Impact Treatment Selection? A Case Study of Abiraterone for Metastatic Prostate Cancer
CONCLUSIONS: Our study suggests that publication of the RCTs was associated with faster uptake of AAP among younger versus older men with newly diagnosed mHSPC, despite the absence of clinical guidance for differential treatment selection. This finding highlights the importance of confirmatory studies among older men, considering the uncertainties of subgroup analyses in RCTs.PMID:36240855 | DOI:10.6004/jnccn.2022.7044 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - October 14, 2022 Category: Cancer & Oncology Authors: Boshen Jiao Yaw A Nyame Josh J Carlson Louis P Garrison Anirban Basu Source Type: research
Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer
CONCLUSIONS This study demonstrated a trend toward a negative correlation between 3-month abiraterone trough levels and PSA levels, but the correlation was not statistically significant. A study with a larger prospective sample size is needed to validate these findings.PMID:36229939 | DOI:10.12659/MSM.938091 (Source: Medical Science Monitor)
Source: Medical Science Monitor - October 14, 2022 Category: Research Authors: Zin W Myint Jill M Kolesar Joseph Robert McCorkle Jianrong Wu Carleton S Ellis Danielle E Otto Peng Wang Source Type: research
Does Clinical Evidence of Heterogeneity Impact Treatment Selection? A Case Study of Abiraterone for Metastatic Prostate Cancer
CONCLUSIONS: Our study suggests that publication of the RCTs was associated with faster uptake of AAP among younger versus older men with newly diagnosed mHSPC, despite the absence of clinical guidance for differential treatment selection. This finding highlights the importance of confirmatory studies among older men, considering the uncertainties of subgroup analyses in RCTs.PMID:36240855 | DOI:10.6004/jnccn.2022.7044 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - October 14, 2022 Category: Cancer & Oncology Authors: Boshen Jiao Yaw A Nyame Josh J Carlson Louis P Garrison Anirban Basu Source Type: research
Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer
CONCLUSIONS This study demonstrated a trend toward a negative correlation between 3-month abiraterone trough levels and PSA levels, but the correlation was not statistically significant. A study with a larger prospective sample size is needed to validate these findings.PMID:36229939 | DOI:10.12659/MSM.938091 (Source: Medical Science Monitor)
Source: Medical Science Monitor - October 14, 2022 Category: Research Authors: Zin W Myint Jill M Kolesar Joseph Robert McCorkle Jianrong Wu Carleton S Ellis Danielle E Otto Peng Wang Source Type: research
